Investigation raises concerns about lack of FDA quality testing for generic drugs

Key Concepts

• Generic Drug Quality: Concerns regarding the consistency and bioequivalence of generic drugs compared to their brand-name counterparts.
• FDA Oversight: The limited and risk-based approach of the FDA in regularly testing the quality and safety of generic drugs, particularly those manufactured overseas.
• Dissolution Issues: Problems with certain generic drugs not dissolving properly in the body, potentially impacting their effectiveness.
• ProPublica Investigation & Tool: A journalistic investigation revealing FDA shortcomings and a consumer tool to check drug manufacturing history.
• Bioequivalence vs. Identicality: The understanding that generics are bioequivalent – meaning they deliver the same amount of active ingredient to the bloodstream – but not necessarily identical to brand-name drugs.

Generic Drug Quality & FDA Regulation

Approximately 90% of prescriptions filled in the U.S. are for generic drugs, driven by insurance companies seeking to lower healthcare costs. While the FDA asserts that all approved generic drugs meet the same standards of quality, strength, purity, and stability as brand-name drugs, a ProPublica investigation revealed a significant lack of regular, independent quality testing by the agency. The investigation highlighted that the FDA “rarely tests the quality of generic drugs,” with a substantial portion being manufactured overseas.

The core issue identified is the FDA’s infrequent testing regime. The agency does not routinely test drugs for quality and safety, even though concerns have been raised by doctors, pharmacists, consumers, academic researchers, and even the Department of Defense. The FDA’s rationale for this limited testing is that sampling a small portion of a drug batch may not accurately reflect overall quality or identify broader trends. Notably, the FDA also does not have a regular testing program for brand-name medications, publicly reporting tested drugs but not conducting systematic evaluations.

Evidence of Dissolution & Efficacy Concerns

Independent testing conducted as part of the ProPublica investigation revealed that certain versions of widely prescribed generic drugs exhibited concerning results due to improper dissolution in the body. This means the active ingredient may not be released and absorbed effectively, potentially leading to reduced efficacy.

This finding corroborates anecdotal evidence gathered from patient experiences. Numerous individuals have reported on social media and to healthcare providers that generic versions of medications, particularly antidepressants like Wellbutrin, “do not feel the same” as the brand-name versions, or that they experience different or worsened symptoms after switching. These concerns are often dismissed by doctors as psychological or unrelated to the medication itself, but the investigation suggests a potential link to variations in generic drug formulations.

Department of Defense Response & Bioequivalence

The Department of Defense is proactively addressing these concerns by independently testing over 40 drugs, specifically focusing on potential contaminants and other quality issues. This demonstrates a recognition of the potential risks associated with relying solely on FDA oversight.

It’s important to note the distinction between bioequivalence and identicality. Generics are required to be bioequivalent to their brand-name counterparts, meaning they deliver the same amount of active ingredient to the bloodstream. However, they are not necessarily identical in terms of inactive ingredients, manufacturing processes, or dissolution rates. These differences can, in some cases, lead to variations in patient response.

ProPublica’s Consumer Tool & Actionable Insights

To empower consumers, ProPublica developed a tool available on their website (propublica.org) that allows individuals to check the manufacturing history of their medications. Users can input information from their pill bottles to determine where the drug was made and whether the manufacturing facility has a history of FDA violations related to substandard manufacturing practices.

The investigation emphasizes that finding a past inspection issue with a factory does not automatically mean a specific drug is unsafe. Consumers are advised to consult with their healthcare provider before making any changes to their medication regimen. The tool’s primary purpose is to provide transparency and access to information previously unavailable to the public, both from the FDA and drug manufacturers.

Notable Quotes

• Reporter: “The FDA is not regularly testing drugs. What we found in the testing is that there were certain versions of widely prescribed generic drugs that have concerning results because they did not dissolve properly in the body.”
• Reporter: “For too long we have not really been asking those questions [about patient experiences with generic drugs].”
• John: “One of the drugs we have tested was an antidepressant. So many people said for so many years that when they switch from the brand of wellbutrin to a generic or one version of the generic to another, they get all kinds of funny symptoms or worse.”

Conclusion

The ProPublica investigation reveals a critical gap in the oversight of generic drug quality in the U.S. While generics are vital for affordable healthcare, the FDA’s limited testing regime and the documented instances of dissolution issues raise concerns about their consistent efficacy. The availability of ProPublica’s consumer tool provides a valuable resource for patients seeking more information about their medications, but ultimately, open communication with healthcare providers remains crucial for addressing individual concerns and ensuring optimal treatment outcomes. The Department of Defense’s proactive testing serves as a model for more robust quality control measures within the pharmaceutical supply chain.